Results 81 to 90 of about 303,632 (262)
Is there a gender effect in polycythemia vera?
Annals of Hematology, 2020 In recent times, there has been a growing interest in understanding the impact of gender on disease biology and clinical outcomes in Philadelphia-negative chronic myeloproliferative neoplasms.
F. Palandri +3 more
semanticscholar +1 more source
Transfusion Medicine, EarlyView.Abstract Background Haemoglobin plays a crucial role in oxygen transport, and any acute deviation will trigger compensatory hemodynamic functions. While the consequences of anaemia are well documented, the effects of haemoglobin reduction in individuals without anaemia remain less explored. Patients with polycythaemia vera and healthy blood donors, who
Rik P. B. Tonino +3 more
wiley +1 more source
Thrombotic and Atherogenetic Predisposition in Polyglobulic Donors
Biomedicines, 2022 This work analyses the results of research regarding the predisposition of genetic hematological risks associated with secondary polyglobulia. The subjects of the study were selected based on shared laboratory markers and basic clinical symptoms.
Nikola Slaninova +8 more
doaj +1 more source
Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms [PDF]
, 2010 We evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34 + cells were transplanted intra-femorally.
Cheung, AMS +4 more
core +1 more source
Haematologica, 2010 Primary myelofibrosis shows histological and pathogenetic overlap with essential thrombocythemia and polycythemia vera. Several diagnostic classifications have been proposed for primary myelofibrosis, although little is known about their clinical utility.
Philip A. Beer +2 more
doaj +1 more source
American journal of hematology/oncology, 2018 Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding,
A. Tefferi, T. Barbui
semanticscholar +1 more source
European Journal of Haematology, Volume 116, Issue 5, Page 545-557, May 2026.ABSTRACT Background Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with a well‐recognized increased risk of thrombotic events, bleeding, and all‐cause mortality, but the frequency of these outcomes during treatment has rarely been assessed in large cohorts.
Anneli Enblom Larsson +5 more
wiley +1 more source
Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. [PDF]
, 2014 Myeloproliferative neoplasms (MPNs) are clonal hematological diseases in which cells of the myelo-erythroid lineage are overproduced and patients are predisposed to leukemic transformation.
de Haan, Gerald +3 more
core +1 more source
Oral Idasanutlin in Patients with Polycythemia Vera.
Blood, 2019 A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem and progenitor cells ...
J. Mascarenhas +12 more
semanticscholar +1 more source
A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo
American Journal of Hematology, Volume 101, Issue 4, Page 697-709, April 2026.ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong +5 more
wiley +1 more source